Table 1 Demographics and clinical characteristics of patients with HER2-amplified breast cancer who received NAC and HER2-targeted therapy, stratified by NAC regimen.
NAC regimen | |||
|---|---|---|---|
Overall N = 6994 | Single agent n = 662 | Multi-agent n = 6253 | |
Age (median, IQR) | 53 (45–62) | 60 (49–70) | 53 (44–61) |
Age category (no, %) | |||
<40 | 954 (13.6) | 54 (8.2) | 892 (14.3) |
40–49 | 1700 (24.3) | 112 (16.9) | 1565 (25.0) |
50–59 | 2147 (30.7) | 161 (24.3) | 1964 (31.4) |
60–69 | 1579 (22.6) | 162 (24.5) | 1400 (22.4) |
70–79 | 549 (7.8) | 133 (20.1) | 408 (6.5) |
80+ | 65 (0.9) | 40 (6.0) | 24 (0.4) |
Race (no, %) | |||
White | 5772 (82.9) | 562 (85.2) | 5145 (82.7) |
Black | 745 (10.7) | 61 (9.2) | 678 (10.9) |
Othera | 443 (6.4) | 37 (5.6) | 399 (6.4) |
Charlson Comorbidity Index (no, %) | |||
0 | 6150 (87.9) | 563 (85.0) | 5518 (88.2) |
1 | 685 (9.8) | 73 (11.0) | 602 (9.6) |
≥2 | 159 (2.3) | 26 (3.9) | 133 (2.1) |
cT stage (no, %) | |||
cT1 | 2242 (32.1) | 273 (41.2) | 1934 (30.9) |
cT2 | 4752 (67.9) | 389 (58.8) | 4319 (69.1) |
Histology (no, %) | |||
Ductal | 6280 (89.8) | 589 (89.0) | 5620 (89.9) |
Lobular | 559 (8.0) | 56 (8.5) | 498 (8.0) |
Other | 155 (2.2) | 17 (2.6) | 135 (2.2) |
Hormone receptor status (no, %) | |||
ER+ | 4709 (67.4) | 444 (67.1) | 4206 (67.3) |
PR+ | 3802 (54.4) | 361 (54.5) | 3401 (54.5) |
Grade (no, %) | |||
Well-differentiated | 312 (4.8) | 40 (6.5) | 267 (4.6) |
Moderately differentiated | 2610 (39.8) | 265 (42.9) | 2311 (39.4) |
Poorly or undifferentiated | 3637 (55.5) | 313 (50.6) | 3290 (56.1) |
Type of surgery (no, %) | |||
Mastectomy | 3444 (49.3) | 308 (46.5) | 3088 (49.4) |
Breast-conserving surgery | 3547 (50.7) | 354 (53.5) | 3162 (50.6) |
Lymph node surgery (no, %) | |||
ALND | 1755 (25.2) | 178 (26.9) | 1550 (24.9) |
SLNB | 4967 (71.2) | 441 (66.6) | 4479 (71.9) |
None | 252 (3.6) | 43 (6.5) | 204 (3.3) |
Radiation therapy (no, %) | 3924 (56.2) | 363 (55.4) | 3527 (56.5) |
Endocrine therapy (no, %) | 4298 (62.7) | 396 (61.8) | 3855 (62.9) |
